Neola Medical AB (publ) (NEOLA.ST) Stock Analysis & Winston Score
Neola Medical AB is a Swedish medical device company focused on monitoring the health of premature babies. Its core product is the NEOLA system, a non-invasive device that continuously monitors lung health in newborns using a technology called electrical impedance tomography. The main customers are neonatal intensive care units (NICUs) in hospitals. The company earns revenue by selling its monitoring hardware and related consumables to hospitals, though it is still in an early commercial stage and currently generates little to no meaningful revenue. Neola Medical operates primarily in Europe, with a small market capitalization of around $100 million, reflecting its pre-revenue status. The key growth driver is gaining regulatory approvals and clinical adoption across more hospitals, but the main risk is that the company continues to burn cash without a clear path to profitability, which is common for early-stage medical device firms.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (3/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Ownership data not available (not counted) (0/15)

